1st Patient Enrolls in Phase 2 Study of Oral Therapy, OPRX-106, for Ulcerative Colitis

1st Patient Enrolls in Phase 2 Study of Oral Therapy, OPRX-106, for Ulcerative Colitis
Protalix BioTherapeutics recently announced that the first patient has been enrolled in the Phase 2 clinical trial evaluating the safety, efficacy and properties of its lead drug candidate, OPRX-106, for the treatment ulcerative colitis (UC), the company announced in a press release. The proof of concept, randomized, open label Phase 2 study (NCT02768974) will evaluate the safety,  efficacy and the therapeutic properties of OPRX-106 in 20 patients with active mild to moderate ulcerative colitis, a long-term condition that causes inflammation and ulcers of the colon and rectum. Eligible patients will be randomly assigned to either 2 mg or 8 mg oral doses of OPRX-106 once daily for eight weeks. The trial's primary endpoint is the number of adverse events, and efficacy will be assessed with relevant disease parameters of the drug, including Mayo score and rectal bleeding. The clinical trial, currently recruiting patients, is being conducted in multiple sites across Israel. Protalix previously concluded a Phase 1 clinical trial (NCT02107833) that evaluated the safety and drug properties of oral OPRX-106 in 15 healthy volunteers. The results, announced in August 2015, showed that OPRX-106 was safe and well-tolerated, and exhibited biological activity in the g
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *